Nuvectis Pharma reports data from Phase 1b study of NXP800

TipRanks11-15

Nuvectis Pharma (NVCT) reported encouraging data from the Phase 1b study evaluating NXP800 in patients with platinum resistant ARID1a-mutated ovarian cancer. Platinum-resistant, ARID1a-mutated ovarian...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483637548?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/xBumZ4QcpNk7wPW_.v5BJw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/060c7819ab2e6aac03de78d24e089052","is_english":true,"pubTime":"2024-11-15 20:45","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483637548","market":"us","top_or_hot":-1,"title":"Nuvectis Pharma reports data from Phase 1b study of NXP800","media":"TipRanks","content":"<div>\n<p>Nuvectis Pharma (NVCT) reported encouraging data from the Phase 1b study evaluating NXP800 in patients with platinum resistant ARID1a-mutated ovarian cancer. Platinum-resistant, ARID1a-mutated ovarian...</p>\n\n<a href=\"https://finance.yahoo.com/news/nuvectis-pharma-reports-data-phase-124518523.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nuvectis Pharma reports data from Phase 1b study of NXP800</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuvectis Pharma reports data from Phase 1b study of NXP800\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-15 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/nuvectis-pharma-reports-data-phase-124518523.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nuvectis Pharma (NVCT) reported encouraging data from the Phase 1b study evaluating NXP800 in patients with platinum resistant ARID1a-mutated ovarian cancer. Platinum-resistant, ARID1a-mutated ovarian...</p>\n\n<a href=\"https://finance.yahoo.com/news/nuvectis-pharma-reports-data-phase-124518523.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVCT","symbol_name":"Nuvectis Pharma, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/nuvectis-pharma-reports-data-phase-124518523.html","article_id":"2483637548","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/xBumZ4QcpNk7wPW_.v5BJw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/060c7819ab2e6aac03de78d24e089052"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nuvectis-pharma-reports-data-phase-124518523.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2483637548","pubTimestamp":1731674718,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Nuvectis Pharma  reported encouraging data from the Phase 1b study evaluating NXP800 in patients with platinum resistant ARID1a-mutated ovarian cancer. Platinum-resistant, ARID1a-mutated ovarian cancer is a serious condition that carries a poor prognosis with an estimated life expectancy of approximately one year from diagnosis. The NXP800 development program in this disease was granted Fast Track Designation by the U.S. Food and Drug Administration and NXP800 was granted Orphan Drug Designation by the FDA for the treatment of ARID1a deficient ovarian, fallopian tube and primary peritoneal cancers. The Phase 1b interim data reported earlier this year included four patients evaluable for safety, of which three experienced Grade 4 thrombocytopenia. Subsequently, in the eight patients treated with NXP800 using the intermittent dosing schedule, the highest grade of thrombocytopenia observed was Grade 2. Other than thrombocytopenia, the most common treatment emergent adverse events included","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVCT":"Nuvectis Pharma, Inc.","BK4139":"生物科技"},"translate_title":"Nuvectis Pharma报告NXP800 1b期研究数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCT":1},"content_text":"Nuvectis Pharma (NVCT) reported encouraging data from the Phase 1b study evaluating NXP800 in patients with platinum resistant ARID1a-mutated ovarian cancer. Platinum-resistant, ARID1a-mutated ovarian cancer is a serious condition that carries a poor prognosis with an estimated life expectancy of approximately one year from diagnosis. The NXP800 development program in this disease was granted Fast Track Designation by the U.S. Food and Drug Administration and NXP800 was granted Orphan Drug Designation by the FDA for the treatment of ARID1a deficient ovarian, fallopian tube and primary peritoneal cancers. The Phase 1b interim data reported earlier this year included four patients evaluable for safety, of which three experienced Grade 4 thrombocytopenia. Subsequently, in the eight patients treated with NXP800 using the intermittent dosing schedule, the highest grade of thrombocytopenia observed was Grade 2. Other than thrombocytopenia, the most common treatment emergent adverse events included nausea, fatigue, vomiting, diarrhea and constipation, the majority of which being Grade 1-2.\n\nPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>\n\n\nSee today’s best-performing stocks on TipRanks >>\n\n\nRead More on NVCT:\n\nNuvectis Pharma Reports Improved Q3 Financials and Clinical Progress\nNuvectis Pharma reports Q3 EPS (24c), consensus (25c)","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483637548"}